[144] Takeda Pharmaceutical Company Limited American SEC Filing

Rhea-AI Filing Summary

Takeda Pharmaceutical Company Limited (NYSE: TAK) submitted a Form 144 notifying the SEC of a proposed discretionary sale of 6,136 American Depositary Shares (ADSs) through Interactive Brokers LLC. At the reference price implied in the filing, the transaction represents an aggregate market value of approximately US$94,617. The shares were originally acquired on 07 July 2025 via vested Restricted Stock Unit (RSU) awards granted by Takeda and are scheduled to be sold on or after 09 July 2025. The number of ADSs to be sold is immaterial relative to Takeda’s total outstanding shares of 123,490,548. No sales by this individual were reported in the prior three-month period, and the filer affirmed that no undisclosed material adverse information is known.

Insights

Financial Analyst

TL;DR: Small insider sale (~US$95k; 0.005% of shares) – informational filing, negligible market impact.

The Form 144 signals an intent by an insider or affiliate to sell 6,136 ADSs. Although insider selling can sometimes be viewed cautiously, the dollar amount and share count are de-minimis versus Takeda’s float. The shares stem from recently vested RSUs, a routine liquidity event rather than a strategic shift. There is no indication of undisclosed adverse information. Overall, this filing is a standard administrative disclosure with neutral implications for investors.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
American Depositary Shares (ADSs)	Interactive Brokers LLC One Pickwick Plaza Greenwich CT 06830	6136	94617.12	123490548	07/09/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ADSs	07/01/2025	Restricted Stock Unit Awards - Vested.	Takeda Pharmaceutical Company Limited			91146	07/01/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many Takeda (TAK) ADSs are being sold per the Form 144?

The filing covers 6,136 American Depositary Shares.

What is the approximate market value of the shares noted in Takeda’s Form 144?

The aggregate market value stated is US$94,617.12.

When is the earliest sale date for the Takeda ADSs?

The filer lists an approximate sale date of 09 July 2025.

How were the Takeda shares acquired by the seller?

They were obtained via vested Restricted Stock Unit awards on 01 July 2025.

What portion of Takeda’s total shares does this sale represent?

6,136 ADSs equal roughly 0.005% of the 123,490,548 shares outstanding, indicating minimal dilution impact.

Which broker will facilitate the proposed sale of Takeda ADSs?

Interactive Brokers LLC, One Pickwick Plaza, Greenwich, CT 06830.